Invega Phase IV examines lower doses
Johnson & Johnson will seek to identify a minimal effective dose for Invega (paliperidone extended-release) during post-marketing studies; a study protocol is due to FDA by April. Data supporting approval for the schizophrenia agent suggest the lower end of the dose-response curve has not been fully evaluated, according to the agency's Dec. 19 approval letter (1"The Pink Sheet" Jan. 1, 2007, p. 5). J&J plans to market Invega with the sales force that currently markets the atypical antipsychotic Risperdal (risperidone), without adding reps. The product, a metabolite of Risperdal, has begun shipping...
You may also be interested in...
J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.